



Friday Five

January 12, 2018

In this issue...

1. [CPSM Invites Stakeholders to Provide Feedback on Draft Standard of Practice for Prescribing Opioids](#)
2. [Model Standards for Pharmacy Compounding of Sterile Preparations - Phase One](#)
3. [Patient Access to Ticagrelor \(Brilinta®\) at Hospital Discharge](#)
4. [Final Reminder: 2018 CPhM and Young Leader Awards Nominations](#)
5. [Professional Development Opportunities](#)

[CPSM Invites Stakeholders to Provide Feedback on Draft Standard of Practice for Prescribing Opioids](#)

The College of Physicians and Surgeons of Manitoba (CPSM) invites its members, stakeholders, and the public to provide feedback on a proposed Standard of Practice for Prescribing Opioids. The consultation addresses the way doctors prescribe opioids to patients in Manitoba, excluding those with active cancer, in palliative care, or at end-of-life.

It is expected that this new Standard will have a direct impact on how some physicians prescribe opioids and on patient care for some of those patients, and therefore, affect other health care resources and practitioners in the province. The College of Pharmacists of Manitoba encourages its members to review the draft Standard and participate in the consultation.

For more information on this important consultation, please visit: <http://cpsm.mb.ca/>

[Model Standards for Pharmacy Compounding of Sterile Preparations - Phase One](#)

The College would like to remind pharmacists involved in compounding of sterile preparations that the deadline for the completion of the first phase of the NAPRA Model Standards for Pharmacy Compounding of Hazardous and Non-Hazardous Sterile Preparations is quickly approaching. This first phase, with an implementation deadline of June 1, 2018, includes the following sections of the Model Standards documents:

- 5.1 Personnel training and assessment
- 5.2 Policies and Procedures
- 6.2 Compounded sterile preparation protocols
- 6.3 Compounded sterile preparation logs
- 6.4 Patient files
- 6.7 Packaging

Professional Development Opportunities

The University of Manitoba Rady Faculty of Health Sciences presents:

[The MEDS Conference](#)

Saturday, January 27, 2018

Online Programs:

[Oral-Systemic Health Education for Non-Dental Healthcare Providers](#)

[Ordering Lab Tests for Manitoba Pharmacists](#)

Visit www.cphm.ca for more information on [Expanded Scope of Practice](#) training.

[Self-Limiting Conditions Independent Study Program](#)

Visit www.cphm.ca for more information on [Expanded Scope of Practice](#) training.

All PD opportunities are listed on the College website under [Upcoming Professional Development Opportunities](#)

- 6.8 Storage
- 6.9 Transport and delivery
- 6.10 Recall procedures
- 6.11 Incident and Accident management procedures
- 6.12 Waste Management
- 7.0 Quality Assurance Program

The deadline for completion of Phase 1 is **June 1, 2018**.

The full implementation schedules can be found on the College's website:

http://www.cphm.ca/site/pharmacy_compounding_standards/hazardous?nav=02

http://www.cphm.ca/site/pharmacy_compounding_standards/non-hazardous?nav=02

Patient Access to Ticagrelor (Brillinta®) at Hospital Discharge

This article was provided by a practicing pharmacist to highlight a potential patient safety risk when therapy with ticagrelor may be interrupted and to share information on ways to prevent this from occurring.

Ticagrelor, combined with low-dose ASA, is currently considered the standard of care for the management of acute coronary syndrome (ACS) including unstable angina (UA), NSTEMI, and STEMI. Immediate and uninterrupted access to ticagrelor is critically important for patients who have been prescribed this medication after experiencing an ACS event. Interruption of antiplatelet therapy following ACS exposes patients to substantial risk of harm, which may include stent thrombosis and reinfarction, which may result in death. Unintentional interruptions in therapy are most likely to occur upon hospital discharge, as patients transition to an outpatient setting.

Understanding how both the federal Non-Insured Health Benefits (NIHB) program and the Manitoba Pharmacare program may be applied for coverage for ticagrelor is important to ensuring timely and reliable patient access to this medication.

NIHB Coverage:

NIHB currently lists ticagrelor as "limited use benefit (prior approval not required)" along with the following criteria for coverage:

"For the treatment of Acute Coronary Syndrome, defined as unstable angina or myocardial infarction, when initiated in hospital in consultation with a Specialist in Cardiology, Cardiac Surgery, Cardiovascular & Thoracic Surgery, Internal Medicine or General Surgery. Treatment must be in combination with low dose ASA. Special authorization may be granted for 12 months^[1]."

It is important to recognize that "prior approval not required" means that **NIHB does not require prior approval or a call to the Drug Exception Centre before the initial fill of ticagrelor (Brillinta®) 90mg**. It should be dispensed immediately, without delay. After one year of ticagrelor 90mg, a form is sent to the prescribing physician to enquire as to whether the therapy is to be continued.

Pharmacare Coverage:

Manitoba Pharmacare previously listed ticagrelor under Part 3: Exception Drug Status (EDS), with the following criteria for coverage:

For the treatment of:

1. Failure on optimal clopidogrel and ASA therapy as defined by definite stent thrombosis, or recurrent STEMI, or NSTEMI or UA after prior revascularization via percutaneous coronary intervention (PCI); OR
2. STEMI and undergoing revascularization via PCI; OR
3. NSTEMI or UA and high risk angiographic anatomy and undergoing revascularization via PCI.

However, as of [Bulletin #96](#), ticagrelor has been reclassified as a Part 2 medication. This change comes into effect on **January 25th, 2018**. With this reclassification, the criteria listed above are still in effect, but the following requirement has been added:

"Treatment must be initiated in hospital and prescribed by a specialist with experience in managing ACS. Approval period 1 year."

According to either program, initiation of ticagrelor must occur in hospital; therefore, the initial outpatient prescription for ticagrelor should be included as part of a hospital discharge prescription. If there is doubt regarding the appropriateness of a ticagrelor prescription, the prescriber should be contacted immediately. It is extremely important that a patient who has experienced an ACS event and/or received an intracoronary stent does not miss any doses of antiplatelet therapy.

[1] Source: Non-Insured Health Benefits – Drug Benefit List Fall 2017:
<http://www.canada.ca/en/health-canada/services/publications/health-system-services/non-insured-health-benefits-drug-benefit-list.html>

Final Reminder: 2018 CPhM and Young Leader Awards Nominations

2018 College of Pharmacists of Manitoba Awards

If you or a pharmacist you know, has made a noteworthy contribution to patient care and safety or the practice of pharmacy, please consider submitting a nomination or application for one of the awards listed in the College of Pharmacists of Manitoba Awards (College Awards) [brochure](#).

The deadline for submitting nominations and applications for the 2018 College Awards is **Tuesday, January 16, 2018**. The College has created [award submission guidelines](#) for your consideration prior to forwarding your nomination to the College's Awards & Nominating Committee.

Please send all nominations or applications by regular mail or email to:

Mail: College of Pharmacists of Manitoba
Attention: The Awards & Nominating Committee – CPhM Awards
200 Taché Avenue
Winnipeg, MB R2H 1A7

Email: info@cphm.ca with the subject line: **Attention: The Awards & Nominating Committee – CPhM Awards**

Awards will be presented during the 2018 Awards Luncheon on **Saturday, May 12, 2018**, at the Manitoba Club in Winnipeg.

2018 Young Leader Awards

The Young Leader Awards celebrate the efforts of up to ten leaders in pharmacy practice. The recipients will receive a plaque to commemorate their contributions to the pharmacy profession and a \$500 cash prize.

The awards are open to recently licensed pharmacists (practicing one to five years post-graduation) and to pharmacy students (interns) in their final year of study who have made a professional contribution to patient care, the pharmacy profession or amongst their colleagues and peers at the University of Manitoba's College of Pharmacy.

If you or someone you know meet these criteria, please submit a nomination or application package including the nominee or applicant's Curriculum Vitae and a summary of their activities and contributions within pharmacy practice or within the University of Manitoba's College of Pharmacy.

The deadline for nominations or applications is **Tuesday, January 16, 2018**.

Please send all nominations or applications by regular mail or email to:

Mail: College of Pharmacists of Manitoba

Attention: The Awards & Nominating Committee – Young Leader Awards

200 Taché Avenue

Winnipeg, MB R2H 1A7

Email: info@cphm.ca with the subject line: **Attention: The Awards & Nominating Committee – Young Leader Awards**

Awards will be presented during the 2018 Awards Luncheon on **Saturday, May 12, 2018**, at the Manitoba Club in Winnipeg.

College of Pharmacists of Manitoba

200 Taché Avenue, Winnipeg, MB R2H 1A7

Phone: 204.233.1411

www.cphm.ca

The *Friday Five* e-bulletin is published by the **College of Pharmacists of Manitoba** and is forwarded to every licenced pharmacist in the Province of Manitoba. Decisions of the College of Pharmacists of Manitoba regarding all matters such as regulations, drug-related incidents, etc., are published in the *Friday Five*. The College of Pharmacists of Manitoba therefore assumes that all pharmacists and pharmacy owners are aware of these matters.

To download a PDF of this e-newsletter, please click [Friday Five & Newsletter ,on www.cphm.ca](http://www.cphm.ca) .